Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Coya and Dr Reddy’s Enter Additional Collaboration Agreement to Develop COYA302 (abatacept + COYA301) to Treat ALS

Dec 6, 2023

Dr. Reddy’s and Coya Therapeutics today announced that they have entered into a development and license agreement for the development and commercialisation of COYA302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).  COYA302 is a co-pack kit containing a combination of low dose IL-2 and CTLA-4 Ig (abatacept).

Under the agreement Coya granted Dr. Reddy’s an exclusive license to commercialise COYA302 in the US, Canada, the EU and the UK for ALS.  The new agreement is in addition to the exclusive worldwide licensing agreement between the companies to use the Dr Reddy’s abatacept biosimilar (to BMS’ Orenica®) to develop and commercialise COYA302 on 20 March 2023.   Coya retains the right to commercialise COYA302 for patients with ALS in Japan, Mexico and South America. Coya will have responsibility for the clinical development of COYA302 and for seeking regulatory approval in US.